QRG Capital Management Inc. Sells 1,330 Shares of United Therapeutics Corporation $UTHR

QRG Capital Management Inc. reduced its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 28.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,360 shares of the biotechnology company’s stock after selling 1,330 shares during the quarter. QRG Capital Management Inc.’s holdings in United Therapeutics were worth $1,992,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Torren Management LLC bought a new position in United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management grew its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics during the 4th quarter worth about $31,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $552.56, for a total value of $4,586,248.00. Following the transaction, the executive vice president owned 45,172 shares of the company’s stock, valued at approximately $24,960,240.32. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $554.61, for a total value of $5,268,795.00. Following the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,468,914.93. This trade represents a 19.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 613,218 shares of company stock valued at $345,644,756 over the last three months. Company insiders own 8.60% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of research reports. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research report on Thursday, May 7th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Cantor Fitzgerald raised their price target on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Finally, Raymond James Financial assumed coverage on United Therapeutics in a report on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.42.

United Therapeutics Stock Up 1.6%

NASDAQ UTHR traded up $8.67 during trading hours on Tuesday, hitting $555.92. The company’s stock had a trading volume of 77,205 shares, compared to its average volume of 494,011. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The firm has a market capitalization of $23.60 billion, a P/E ratio of 20.51, a PEG ratio of 1.82 and a beta of 0.58. The stock has a fifty day moving average of $557.83 and a 200 day moving average of $528.36.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same period in the prior year, the firm posted $6.63 EPS. On average, analysts predict that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.